SCHEMBL24310520

SCHEMBL24310520

Cc1ccccc1-c1nc(NS(=O)(=O)c2cnn(C)c2)nc(Oc2cccc(N3CCN(C)CC3)c2F)c1C(F)(F)C(F)(F)F

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR1A P08908 4/20 0.34
▸ HTR7 P34969 4/20 0.34
▸ EGFR P00533 2/20 0.32
▸ MET P08581 2/20 0.32
▸ INSR P06213 1/20 0.32
▸ SCN9A Q15858 2/20 0.32
▸ BRAF P15056 1/20 0.32
▸ TACR1 P25103 2/20 0.32
▸ HTR6 P50406 4/20 0.31
▸ BRD4 O60885 3/20 0.31
▸ JAK1 P23458 1/20 0.31
▸ JAK3 P52333 1/20 0.31
▸ BRDT Q58F21 1/20 0.31
▸ TNK2 Q07912 1/20 0.31
▸ DRD2 P14416 1/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29566949 1.00 HTR1A (0.34) HTR1AHTR7EGFRMETINSR
SCHEMBL26811673 0.92 HTR1A (0.33) HTR1AHTR7EGFRMETINSR
SCHEMBL24310107 0.88 HTR1A (0.36) HTR1AHTR7EGFRMETINSR
SCHEMBL29567201 0.88 AXL (0.33) HTR1AHTR7EGFRMETINSR
SCHEMBL29566869 0.88 HTR1A (0.36) HTR1AHTR7EGFRMETINSR
SCHEMBL24310787 0.88 AXL (0.33) HTR1AHTR7EGFRMETINSR
SCHEMBL24310083 0.87 HTR1A (0.39) HTR1AHTR7SCN9ABRAFHTR6
SCHEMBL29566574 0.87 HTR1A (0.34) HTR1AHTR7EGFRSCN9ABRAF
SCHEMBL26808972 0.87 HTR1A (0.34) HTR1AHTR7EGFRSCN9ABRAF
SCHEMBL24310497 0.87 RAD52 (0.36) EGFRMETINSRBRD4JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B HTR1A 4018/4885HTR7 3833/4885EGFR 818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback